In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZOVIRAX VIRAL RESISTANCE POTENTIAL IS PRIMARY ISSUE TO BE ADDRESSED BY FDA

This article was originally published in The Tan Sheet

Executive Summary

ZOVIRAX VIRAL RESISTANCE POTENTIAL IS PRIMARY ISSUE TO BE ADDRESSED BY FDA in reviewing Burroughs Wellcome's Rx-to-OTC switch application for the treatment of recurrent genital herpes, FDA's Nonprescription Drugs and Antiviral Drugs Advisory Committees agreed at a joint May 19 meeting held after a public hearing on the switch. The issue of vital resistance topped a list of issues prepared by the two committees for FDA in reviewing the Zovirax (acyclovir) switch application and in preparing for the joint advisory committee's review in July.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel